EU/3/16/1794: Orphan designation for the diagnosis of gastrointestinal stromal tumours
Table of contents
On 12 December 2016 orphan designation (EU/3/16/1794) was granted by the European Commission to Advanced Accelerator Applications, France, for 68Ga-DOTA-pABzA-DIG-dPhe-Gln-Trp-Ala-Val-Gly-His-NHCH[(CH2-CH(CH3)2]2 (also known as 68Ga-NeoBOMB1) for the diagnosis of gastrointestinal stromal tumours.
Diagnosis of gastrointestinal stromal tumours
|Orphan designation status||
|EU designation number||
|Date of designation||
Advanced Accelerator Applications
20 rue Diesel
Tel. +33 4 50 99 30 76
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: